Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672775 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
A Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, sponsored by Agensys.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 9
- Study locations
NCT01672775 is a Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology that has completed, run by Agensys. The registered enrollment target is 34 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (88% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT01672775, a Phase 1 study of Carcinoma, Renal Cell and Renal Cell Carcinoma of Papillary Histology, has completed, sponsored by Agensys.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
Conditions Studied
Interventions
- DRUG AGS-16C3F
Study Locations (9)
Michigan
- Site US00005 University of Michigan Medical Center - Ann Arbor
- Site US00003 Karmanos Cancer Institute - Detroit
New York
- Site US00004 Roswell Park Cancer Institute - Buffalo
- Site US00002 Memorial Sloan-Kettering Cancer Center - New York
Washington
- Site US00001 Seattle Cancer Care Alliance - Seattle
Alberta
- Site CA00006 Cross Cancer Institute - Edmonton
British Columbia
- Site CA00008 British Columbia Cancer Agency - Vancouver
Ontario
- Site CA00009 London Health Sciences Centre - London
Quebec
- Site CA00007 Jewish General Hospital - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-07-18 |
| Est. Completion | 2017-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672775
The ClinicalTrials.gov registry entry for NCT01672775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (88% lower). The listed sponsor is Agensys, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which AGS-16C3F is the first listed.
NCT01672775 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Michigan, New York, Washington.
Frequently Asked Questions
What is clinical trial NCT01672775 about?
NCT01672775 is a clinical study titled "A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology". The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).
What is the current status of trial NCT01672775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-07-18. Estimated completion is 2017-02-21.
What conditions does trial NCT01672775 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology.
What interventions are being tested in trial NCT01672775?
The interventions under investigation include: AGS-16C3F (DRUG).
Who is sponsoring clinical trial NCT01672775?
This trial is sponsored by Agensys, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01672775 being conducted?
This trial has 9 study locations across Michigan, New York, Washington, Alberta, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Carcinoma, Renal Cell
All registered trials for this condition
Renal Cell Carcinoma of Papillary Histology
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.